SeraNovo Signs License Agreement with Carna Biosciences

Pharmaceutical Technology Editors

Start-up company, SeraNovo, has revealed that it has signed a license agreement with Carna Biosciences to expand the existing collaboration and jointly develop an oral formulation of Carna’s kinase inhibitor with increase bioavailability.

Start-up company, SeraNovo, has revealed that it has signed a license agreement with Carna Biosciences to expand the existing collaboration and jointly develop an oral formulation of Carna’s kinase inhibitor with increase bioavailability.

The terms of the agreement, which were announced in an Oct. 30, 2019 press release, will see SeraNovo formulate one of Carna’s drugs using its proprietary Deep Eutectic Solvent (DES) formulation platform to improve bioavailability. It is anticipated that the final formulation will include an optimized combination of a DES along with one or more polymeric precipitation inhibitors as well as Carna’s kinase inhibitor.

“We are very excited that we have set up this important partnership with Carna Biosciences. We are confident this is just the first step in a long and fruitful partnership with an industry leader,” said Niall Hodgins, chief executive officer of SeraNovo in the press release. “As a start-up company, this partnership represents excellent validation for our breakthrough formulation technology.”

Source: SeraNovo